Abrdn Healthcare Investors (HQH) Stock
Focused global healthcare fund managed by abrdn. Here's the price, business snapshot, and what's worth knowing about Abrdn Healthcare Investors in September 2026.
abrdn Healthcare Investors (HQH) is a London-listed closed‑end investment trust that seeks long‑term capital growth and income from a focused portfolio of global healthcare equities. Managed by abrdn, the trust typically invests across pharmaceuticals, biotechnology, medical devices and healthcare services, often holding a concentrated set of high‑conviction positions. As a closed‑end vehicle, HQH can trade at a premium or discount to its net asset value (NAV) and its market capitalisation is roughly $1.04 billion. Key attractions for investors include sector exposure to ageing populations and innovation in drugs and devices, but the concentrated, sector‑specific nature of the trust brings heightened sensitivity to regulatory decisions, clinical trial results and R&D outcomes. Currency movements and geographic exposure can also affect returns. This information is educational only and not personal advice; investors should consider their risk tolerance, read the trust’s latest factsheet and consult a financial adviser before investing.
Sixth Month Growth Performance
Stock Performance Snapshot
Financial Health
abrdn Healthcare Investors has modest revenue and low profit margins, indicating average financial performance.
Dividend
ABRDN Healthcare Investors offers a high dividend yield of 10.75%, making it appealing for income-focused investors. If you invested $1000 you would be paid $107.50 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Active healthcare picks
Manager selects concentrated positions across pharma, biotech and devices to capture innovation-led growth, though concentrated exposure can increase volatility.
Global sector exposure
Invests internationally across regions and sub‑sectors, offering diversification within healthcare while remaining exposed to different regulatory and currency risks.
R&D-driven outcomes
Healthcare returns often hinge on clinical trials and approvals — potential for strong upside but also binary downside risks for individual stocks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
